ASTRAZENECA'S Symbicort Turbuhaler 200/6 and Symbicort Rapihaler 100/3 are now available for the treatment of asthma in patients aged 12 years and over, through the Pharmaceutical Benefits Scheme (PBS).
The listing will enable health professionals to prescribe Symbicort (budesonide/formoterol [eformoterol] fumarate dihydrate) to patients with mild asthma, without daily maintenance treatment, through the PBS.
With approximately 2.7 million Australians living with the condition, Asthma Australia CEO, Michele Goldman, said that maintaining control of a patient's condition was one of the key ways to protect against a flare-up and improve quality of life.
The above article was sent to subscribers in Pharmacy Daily's issue from 01 Jun 20
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Jun 20
